Corpus ID: 6911531

Involution of EruptiveMelanocytic Nevi on Combination BRAF andMEK Inhibitor Therapy

@inproceedings{Chen2014InvolutionOE,
  title={Involution of EruptiveMelanocytic Nevi on Combination BRAF andMEK Inhibitor Therapy},
  author={F. Chen and D. Tseng and S. Reddy and A. Daud and S. Swetter},
  year={2014}
}
E ruptive melanocytic nevi (EMN) have been described as the sudden-onset development of numerous melanocytic nevi in association with bullous diseases or conditions of immunosuppression, including patients with human immunodeficiency virus, or those who have undergone chemotherapy or organ transplantation. In the recent literature, EMN have been described in patients receiving sorafenib, a multikinase inhibitor,1 and vemurafenib, a selective BRAF inhibitor (BRAFi). No case reports, to our… Expand

Figures from this paper

References

SHOWING 1-10 OF 14 REFERENCES
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Melanoma: from mutations to medicine.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
...
1
2
...